# llms.txt
# Guidance for Large Language Model (LLM) crawlers
# Website: PEMAZYRE
> PEMAZYRE (pemigatinib) is a targeted treatment for adults with previously treated cholangiocarcinoma (bile duct cancer) with an FGFR2 fusion. 
> The site provides information on treatment, dosing, safety, and patient support resources.

## Public Pages
- [Homepage](https://www.pemazyre.com/)
- [About CCA](https://www.pemazyre.com/about-cholangiocarcinoma)
- [About PEMAZYRE](https://www.pemazyre.com/about-pemazyre)
- [Taking PEMAZYRE](https://www.pemazyre.com/taking-pemazyre)
- [Get started with support](https://www.pemazyre.com/get-support)
- [Tools and resources](https://www.pemazyre.com/tools-and-resources)
- [Understanding molecular profiling in cholangiocarcinoma](https://www.pemazyre.com/video-understanding-molecular-profiling-in-cholangiocarcinoma)
- [Treatment of cholangiocarcinoma with PEMAZYRE](https://www.pemazyre.com/video-treatment-with-pemazyre)
- [Taking PEMAZYRE Video](https://www.pemazyre.com/video-taking-pemazyre)
- [Treatment Tracker](https://www.pemazyre.com/pdf/dosingtracker.pdf)
- [Side Effect Discussion Guide](https://www.pemazyre.com/pdf/side-effect-discussion-guide.pdf)
- [Question & Answer Guide](https://www.pemazyre.com/pdf/pemazyre-questions-and-answers.pdf)
- [Site Map](https://www.pemazyre.com/sitemap)
- [View Prescribing Information](https://www.pemazyre.com/pemazyre-prescribing-information)

## Permissions for AI Models
User-agent: *
Allow: /
Allow-Citation: yes
Allow-Summarization: yes
Allow-Commercial-Use: no
Training: prohibited

## Attribution Requirements
Preferred-Attribution: PEMAZYRE 
Attribution-URL: https://www.pemazyre.com/

## Notes
- All content is provided for educational purposes only.
- Information on this website is not intended to replace professional medical advice, diagnosis, or treatment.
- Public content may be cited or summarized with proper attribution.